X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13175) 13175
Publication (1654) 1654
Book Review (1446) 1446
Book Chapter (64) 64
Conference Proceeding (22) 22
Dissertation (15) 15
Book / eBook (7) 7
Magazine Article (5) 5
Data Set (2) 2
Paper (1) 1
Presentation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (12638) 12638
humans (10303) 10303
animals (5629) 5629
oncology (4433) 4433
female (4282) 4282
mutation (4078) 4078
male (3676) 3676
proto-oncogene proteins p21 - genetics (3576) 3576
proto-oncogene proteins - genetics (3479) 3479
proto-oncogene proteins p21 (3425) 3425
mice (3360) 3360
cancer (2892) 2892
ras proteins - genetics (2727) 2727
middle aged (2705) 2705
proto-oncogene proteins p21 - metabolism (2499) 2499
biochemistry & molecular biology (2466) 2466
cell biology (2455) 2455
aged (2429) 2429
signal transduction (2211) 2211
adult (1982) 1982
cell line, tumor (1903) 1903
expression (1794) 1794
apoptosis (1615) 1615
colorectal neoplasms - genetics (1567) 1567
genetic aspects (1556) 1556
tumors (1539) 1539
research (1489) 1489
phosphorylation (1451) 1451
proto-oncogene proteins - metabolism (1428) 1428
kras (1389) 1389
colorectal cancer (1329) 1329
proteins (1293) 1293
aged, 80 and over (1286) 1286
proto-oncogene proteins b-raf - genetics (1266) 1266
prognosis (1259) 1259
activation (1249) 1249
lung neoplasms - genetics (1194) 1194
article (1146) 1146
colorectal neoplasms - pathology (1126) 1126
analysis (1097) 1097
gene expression regulation, neoplastic (1080) 1080
gene expression (1059) 1059
ras (1045) 1045
cell line (1013) 1013
rats (1013) 1013
pathology (1000) 1000
genes, ras (968) 968
adenocarcinoma - genetics (943) 943
chemotherapy (942) 942
cell proliferation (940) 940
immunohistochemistry (929) 929
mutations (929) 929
transfection (873) 873
dna mutational analysis (857) 857
lung neoplasms - pathology (854) 854
molecular sequence data (854) 854
multidisciplinary sciences (852) 852
genetics & heredity (846) 846
cells, cultured (835) 835
cells (834) 834
proto-oncogene proteins c-akt - metabolism (833) 833
metastasis (832) 832
tumor suppressor protein p53 - genetics (818) 818
carcinoma (817) 817
mutation - genetics (814) 814
cetuximab (802) 802
gene (798) 798
growth (779) 779
genes (773) 773
p53 (764) 764
cell cycle (754) 754
adenocarcinoma (753) 753
oncogenes (744) 744
abridged index medicus (743) 743
tumor suppressor protein p53 - metabolism (741) 741
colorectal neoplasms - drug therapy (740) 740
kinases (731) 731
ras proteins - metabolism (731) 731
receptor, epidermal growth factor - genetics (727) 727
survival (725) 725
k-ras (721) 721
tumor cells, cultured (717) 717
base sequence (715) 715
research article (708) 708
health aspects (704) 704
biomarkers, tumor - genetics (698) 698
care and treatment (695) 695
apoptosis - drug effects (693) 693
signal transduction - drug effects (690) 690
adenocarcinoma - pathology (671) 671
neoplasms (669) 669
lung cancer (663) 663
antineoplastic agents - pharmacology (655) 655
gene mutations (655) 655
neoplasm staging (649) 649
antineoplastic agents - therapeutic use (635) 635
physiological aspects (634) 634
polymerase chain reaction (621) 621
blotting, western (619) 619
amino acid sequence (615) 615
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12844) 12844
Chinese (134) 134
Japanese (83) 83
French (33) 33
German (33) 33
Russian (28) 28
Spanish (10) 10
Czech (7) 7
Hungarian (7) 7
Hebrew (5) 5
Polish (4) 4
Portuguese (3) 3
Dutch (2) 2
Italian (2) 2
Croatian (1) 1
Finnish (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 09/2013, Volume 369, Issue 11, pp. 1023 - 1034
Patients who have colorectal cancer with RAS mutations in exon 2 are unlikely to respond to EGFR blockers. A retrospective analysis of tumors containing other,... 
SURVIVAL | 1ST-LINE TREATMENT | LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | RANDOMIZED PHASE-III | CETUXIMAB PLUS IRINOTECAN | BRAF | KRAS CODON 12 | FLUOROURACIL | CHEMOTHERAPY | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Membrane Proteins - genetics | Colorectal Neoplasms - genetics | Humans | Antibodies, Monoclonal - therapeutic use | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Fluorouracil - therapeutic use | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Colorectal Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Leucovorin - therapeutic use | Mutation | Colorectal Neoplasms - pathology | Genes, ras | Organoplatinum Compounds - therapeutic use | Care and treatment | Dosage and administration | Research | Gene mutations | Panitumumab | Colorectal cancer | Hypothesis testing | Medical research | Statistical analysis | Epidermal growth factor receptors | Colorectal carcinoma | Metastasis | Cancer therapies | Survival | Patients | Metastases | Studies | Hypotheses | Chemotherapy | Epidermal growth factor | Oxaliplatin | Testing laboratories | Medical prognosis | Biomarkers | Deoxyribonucleic acid--DNA | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Nature, ISSN 0028-0836, 04/2013, Volume 496, Issue 7443, pp. 101 - 105
Journal Article
Cancer Cell, ISSN 1535-6108, 02/2014, Volume 25, Issue 2, pp. 243 - 256
Mutations in are prevalent in human cancers and universally predictive of resistance to anticancer therapeutics. Although it is widely accepted that... 
ACTIVATION | INHIBITION | ONCOGENIC RAS | TUMOR PROGRESSION | CHK1 | ONCOLOGY | INITIATION | COMBINATION | SUPPRESSION | ATR | KINASES | CELL BIOLOGY | Neoplasms - metabolism | Protein Kinases - metabolism | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) - genetics | Humans | ras Proteins - metabolism | Drug Resistance, Neoplasm | Phosphatidylinositol 3-Kinases - metabolism | GTP Phosphohydrolases - antagonists & inhibitors | Ribosomal Protein S6 Kinases, 90-kDa - metabolism | Flow Cytometry | Neoplasms - genetics | DNA Damage - genetics | Female | Antineoplastic Agents - pharmacology | Membrane Proteins - metabolism | Phosphorylation - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Proto-Oncogene Proteins p21(ras) - metabolism | DNA Damage - drug effects | Proto-Oncogene Proteins - metabolism | Cell Survival - drug effects | Membrane Proteins - genetics | Proto-Oncogene Proteins - genetics | Mutation - genetics | Animals | GTP Phosphohydrolases - metabolism | Membrane Proteins - antagonists & inhibitors | Mitogen-Activated Protein Kinase 3 - metabolism | GTP Phosphohydrolases - genetics | Mice, Nude | Proto-Oncogene Proteins p21(ras) - antagonists & inhibitors | Checkpoint Kinase 1 | Mice | Cell Transformation, Neoplastic - pathology | Neoplasms - pathology | Mitogen-Activated Protein Kinase 1 - metabolism | Chemotherapy | DNA damage | DNA | Genetic research | DNA repair | Cancer | Tumors | Index Medicus
Journal Article
Journal Article
Nature Medicine, ISSN 1078-8956, 09/2015, Volume 21, Issue 9, pp. 1038 - 1047
Journal Article
Journal Article
Cell, ISSN 0092-8674, 02/2017, Volume 168, Issue 5, pp. 878 - 889.e29
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2012, Volume 18, Issue 8, pp. 2316 - 2325
Purpose: This study evaluated the clinical relevance of the dual-targeting strategy involving PI3K/AKT/mTOR and RAF/MEK/ERK pathways. Experimental Design: We... 
COLON-CANCER | METASTATIC MELANOMA | PIK3CA MUTATIONS | PI3K | ONCOLOGY | COLORECTAL-CANCER | RESISTANCE | BRAF | ANTITUMOR-ACTIVITY | MEK INHIBITORS | TUMORS | Neoplasms - metabolism | Extracellular Signal-Regulated MAP Kinases - drug effects | TOR Serine-Threonine Kinases - metabolism | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Middle Aged | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Male | Phosphatidylinositol 3-Kinases - metabolism | Extracellular Signal-Regulated MAP Kinases - metabolism | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Extracellular Signal-Regulated MAP Kinases - genetics | Proto-Oncogene Proteins c-akt - genetics | TOR Serine-Threonine Kinases - antagonists & inhibitors | Young Adult | MAP Kinase Signaling System - genetics | TOR Serine-Threonine Kinases - genetics | Neoplasms - genetics | Aged, 80 and over | Adult | Female | Proto-Oncogene Proteins c-akt - metabolism | Proto-Oncogene Proteins p21(ras) - metabolism | Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | MAP Kinase Signaling System - drug effects | Proto-Oncogene Proteins B-raf - genetics | Proto-Oncogene Proteins p21(ras) - antagonists & inhibitors | Adolescent | Aged | Mutation | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Index Medicus
Journal Article
Journal Article